![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EPIX RECEIVES APPROVABLE LETTER FOR BLOOD POOL CONTRAST AGENT
EPIX RECEIVES APPROVABLE LETTER FOR BLOOD POOL CONTRAST AGENT
Epix Pharmaceuticals has received an approvable letter from the FDA for MS-325, a blood pool management agent for magnetic resonance angiography (MRA).
The FDA requested additional information from Epix to support the application for MS-325 (gadofosveset trisodium) in enhanced MRA. Epix is developing the agent in conjunction with Schering AG.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct